+------------------------------------------------------------------------------+
MORE: UCB And Hospira May Be M&A Targets for Astra, Citi Says 2013-11-21 11:07:32.693 GMT
By Simeon Bennett Nov. 21 (Bloomberg) -- Buying UCB, Hospira or Actelion would give AstraZeneca “long runway” assets to offset genericization over next 3y, Citigroup analyst Andrew Baum says in note today. * Restructuring diabetes JV with Bristol-Myers Squibb, coupled with acquisition such as Actelion, could add 24% to core EPS: Baum * Deal like Actelion wouldn’t jeopardize GBP1.8 dividend: Baum * Actelion would complement AstraZeneca’s stated growth platforms in cardiovascular, respiratory medicine: Baum * AstraZeneca could benefit from Actelion’s 15% effective tax rate: Baum * AstraZeneca was among bidders for Onyx, people familiar told Bloomberg in July * NOTE: Actelion Rises After Citi Says It Could Be M&A Target for Astra * NOTE: AstraZeneca, Pfizer, Novartis Among Suitors for Onyx Pharma * NOTE: Don’t See Need for Large Acquisition, AstraZeneca CEO Says
For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>
To contact the reporter on this story: Simeon Bennett in Geneva at +41-22-317-9238 or sbennett9@bloomberg.net
To contact the editor responsible for this story: Phil Serafino at +33-1-5530-6277 or pserafino@bloomberg.net